Wedbush Cuts Artiva Biotherapeutics Target to $4 From $40, Downgrades Rating
Wedbush lowered its price target on Artiva Biotherapeutics to $4.00 from $40.00 and cut its rating to Neutral from Outperform, per Dow Jones Newswires.
- published on Newsmetry
- original source published
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner. connect the api →
what happened
Wedbush lowered its price target on Artiva Biotherapeutics (ARTV) to $4.00 per share from $40.00. The firm also downgraded the stock to Neutral from Outperform.
Dow Jones Newswires reported the change, citing Benzinga's ratings data. The item concerns a single analyst rating on the company.
why it matters
Rating changes on individual companies mainly matter to shareholders and a narrow group of investors. For the broader market the signal is limited, but a cut of this size shows how one brokerage reassessed the stock's outlook.
tags
instruments
sources
- Artiva Biotherapeutics Price Target Cut to $4.00/Share From $40.00 by Wedbush — Dow Jones Newswires, 27 October 2026 at 14:20 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner.
get stories in real time ↗